Company: Amphivena Therapeutics Inc.
Job title: Chief Scientific Officer
AMV564 Depletes MDSC & Activates T Cells in Cancer Patients 1:45 pm
AMV564 is a clinical-stage bivalent T cell engager that selectively targets myeloid derived suppressor cells (MDSC) Subcutaneous injection of AMV564 is well tolerated with early evidence of clinical activity in cancer patients in a phase 1 study Pharmacodynamic data from patients treated with AMV564 demonstrate significant decreases in MDSC in parallel with evidence of CD8…Read more
day: Day One